In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Valneva SE

B+L/Novaliq Hope Miebo Can Stand Out In Crowded Dry Eye Field

The companies got US FDA approval for the drug, which they said is the only approved medicine that targets tear evaporation rather than tear production, though its mechanism is not fully understood.

Approvals Ophthalmic

Digital Health Roundup: HIMSS, Cardio Conversations, ChatGPT And New FDA Guidances

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb discusses how two medtech CEOs are and aren’t using ChatGPT in their businesses while Reed Miller talks about his “Cardio Conversations” podcast interviews with Quentin Blackford, CEO of iRhythm, and Rob Krummen, CEO of Vektor Medical. Washington, DC-based reporter Hannah Daniel reviews highlights from the HIMSS conference and the latest updates on FDA guidances.

Artificial Intelligence Business Strategies

News We’re Watching: AngelMed Becomes Avertix, 3M Layoffs, FDA Warns On COVID Test Use

This week, cardiac monitoring firm AngelMed announced its new name; Tempus nabbed FDA approval for its tumor profiling test; and iRhythm revealed that it’s been subpoenaed by the US Department of Justice.

Commercial Policy

Finance Watch: Mega-Rounds Make A Comeback, But Will VC Funding Totals Rise Too?

Private Company Edition: Venture capital mega-rounds of $100m or more held steady in April after a slow January and February then a surge in March, but VC fundraising is down overall this year. In recent raises, Enveda series B expanded to $119m, Vedanta brought in $106.5m and Convergent raised $90m.

Finance Watch Business Strategies
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Synthesis Technologies, Production Processes
    • Transgenics
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • BliNK Biomedical SAS
    • Crucell Sweden AB
    • Iomai Corporation
    • Intercell USA, Inc.
    • Intercell AG, Vivalis
UsernamePublicRestriction

Register